Group 1 - Analysts project Seagate (STX) will announce quarterly earnings of $2.46 per share, a 134.3% increase year over year [1] - Revenues are expected to reach $2.41 billion, reflecting a 27.5% increase from the same quarter last year [1] - The consensus EPS estimate has been revised 0.5% higher over the last 30 days, indicating a collective reevaluation by analysts [2] Group 2 - Analysts suggest that 'Revenue by Product Line- HDD- Legacy' will be $245.91 million, a decrease of 15.2% year over year [5] - The estimate for 'Revenue by Product Line- HDD- Mass Capacity' is projected at $2.01 billion, an increase of 39.6% from the prior-year quarter [5] - The consensus estimate for 'Capacity Shipped - Total' and 'Capacity Shipped - Legacy' remains N/A, with no prior year figures available [6] Group 3 - Over the past month, Seagate shares have returned +6.7%, outperforming the Zacks S&P 500 composite's +4.9% change [6] - Seagate currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [6]

Core Insights - EMCOR Group, Inc. is set to report its second-quarter 2025 results on July 31, with expectations of continued growth in earnings and revenue driven by strong demand in key sectors [1][10]. Financial Performance - In the last reported quarter, EMCOR achieved earnings per share (EPS) of $5.41, surpassing expectations by 18.4% and reflecting a 30% increase year-over-year [2]. - Revenue for the last quarter was $3.87 billion, marking a 12.7% year-over-year growth and exceeding the Zacks Consensus Estimate by 1.9% [2]. - The company's adjusted operating margin expanded to 8.5%, supported by prefabrication and virtual design capabilities [2]. - The backlog (Remaining Performance Obligations, or RPOs) grew 28.1% year-over-year to $11.8 billion [2]. Future Estimates - The Zacks Consensus Estimate for the second-quarter EPS is $5.68, indicating an 8.2% growth from the previous year, while the revenue estimate is $4.1 billion, suggesting an 11.9% year-over-year increase [4]. - For the full year 2025, EMCOR is expected to see a 12.7% growth in revenues and a 9.6% growth in EPS compared to the previous year [4]. Market Dynamics - Despite inflationary pressures and economic uncertainty, EMCOR's revenues and earnings are anticipated to have increased due to heightened project flows in high-tech manufacturing and network communications sectors, particularly in semiconductor and data center construction [5][6]. - The Electrical Construction segment is benefiting from strong demand in data centers, with 85% of the network and communications backlog linked to this area [7]. - The Mechanical Construction segment shows strength in healthcare, institutional, and water/wastewater markets, bolstered by the integration of Miller Electric [7]. Segment Performance - The U.S. Building Services segment is expected to improve in the second quarter, with a shift towards higher-margin technician-based services [8]. - The Industrial Services segment is projected to recover from weather-related disruptions in the first quarter, aided by a normalization of credit loss provisions [9]. - The U.K. Building Services segment is expected to maintain stable performance, with healthy project demand despite initial mobilization costs affecting margins [11]. Overall Outlook - EMCOR anticipates a strong second quarter in 2025, driven by construction segments, a rebound in Industrial Services, and margin resilience across the board [12].

Core Insights - C.H. Robinson Worldwide, Inc. (CHRW) is set to report its second-quarter 2025 results on July 30, after market close, with a history of positive earnings surprises, averaging a beat of 14.52% over the last four quarters [1][5] Financial Performance Expectations - The Zacks Consensus Estimate for CHRW's Q2 2025 earnings has been revised downward by 1.68% to $1.17 per share, indicating a 1.74% growth from the previous year [3] - Revenue estimates for Q2 2025 are projected at $4.22 billion, reflecting a 5.87% decrease year over year, primarily due to the divestiture of the Europe Surface Transportation business and lower volumes in North America truckload services [4][5] Segment Performance - North American Surface Transportation's Q2 revenue is estimated at $2.97 billion, a 0.8% decrease from the previous year, with lower truckload volumes impacting performance [6] - Global Forwarding's Q2 revenue is pegged at $783 million, indicating a 14.9% decline year over year, attributed to lower pricing in ocean services [7] - The All Other and Corporate segment's Q2 revenue is estimated at $467 million, an 18.3% decline from the previous year, driven by lower transaction volumes and the divestiture of the Europe Surface Transportation business [8] Earnings Prediction Model - The current model does not predict an earnings beat for CHRW, with an Earnings ESP of -2.27% and a Zacks Rank of 3, indicating a hold position [9]

Core Insights - Humana Inc. (HUM) is expected to report second-quarter 2025 results on July 30, with earnings estimated at $6.32 per share and revenues at $31.78 billion, reflecting an 8.2% year-over-year growth in revenues despite a 9.2% decline in earnings [2][6] Financial Performance Expectations - The full-year 2025 revenue estimate for Humana is $126.1 billion, indicating a 7.6% year-over-year increase, while the EPS for the current year is projected at $16.37, showing a 1% gain year-over-year [3] - Humana has consistently beaten earnings estimates in the past four quarters, with an average surprise of 14.3% [3] Earnings Prediction Model - The company has a positive Earnings ESP of +10.51% and a Zacks Rank of 3 (Hold), suggesting a likelihood of an earnings beat this quarter [4] Revenue and Income Growth - The consensus estimate for second-quarter premiums indicates a 7.4% increase year-over-year, with total Medicare expected to grow by 3.8% [7] - Operating income from the Insurance unit is projected to grow by 21.4% compared to the previous year, contributing positively to earnings [8] Cost and Membership Challenges - The CenterWell unit is expected to see a 0.4% decline in operating income, and investment income is projected to drop nearly 9% year-over-year [9] - Total operating costs are anticipated to exceed $30 billion, increasing by more than 5%, which may negatively impact the bottom line [9] - The overall benefits expense ratio is expected to worsen to 89.47%, and insurance membership is projected to decline by 5.8% year-over-year [10] Peer Performance Comparison - Centene Corporation reported a second-quarter adjusted loss per share of 16 cents, missing estimates due to rising medical costs and declining service revenues [11] - Molina Healthcare reported adjusted EPS of $5.48, slightly missing estimates due to higher medical care costs [12] - Elevance Health reported adjusted EPS of $8.84, also missing estimates due to rising medical costs, despite some offset from increasing premiums [12]

Core Viewpoint - Biogen is expected to report second-quarter 2025 results on July 31, with sales and earnings estimates at $2.32 billion and $3.95 per share, respectively, following a previous earnings miss of 7.4% [1][11]. Group 1: Sales Performance - Lower sales of Biogen's multiple sclerosis (MS) drugs are anticipated, likely offset by revenue growth from new products [2]. - Sales of Tecfidera and Tysabri are projected to decline due to generic and biosimilar competition, with estimates for Tecfidera at $178.0 million and Tysabri at $373.0 million [3][4]. - Vumerity's sales are expected to rise, with estimates at $70.0 million and $181.9 million [4]. - Spinraza's sales are estimated at $397.0 million and $403.0 million, with a potential reversal in favorable shipment timing impacting second-quarter results [5]. - Skyclarys is likely to see mixed dynamics in the U.S. and global markets, with growth driven more by ex-U.S. sales [6][9]. Group 2: Collaborations and New Products - Biogen's collaboration with Sage Therapeutics for Zurzuvae involves shared profits and losses, with strong patient demand expected to continue [7]. - Alzheimer's collaboration revenues, including Biogen's share from Leqembi, are expected to rise, with Leqembi's sales improving sequentially [8][10]. Group 3: Earnings Expectations - Biogen's earnings surprise history shows a mixed performance, with a four-quarter average surprise of 8.36% [11]. - The Earnings ESP for Biogen is -0.85%, indicating a lower likelihood of an earnings beat this quarter [14].

Core Viewpoint - The market anticipates CPI Card Group Inc. (PMTS) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.56 per share, reflecting a year-over-year increase of +9.8%, while revenues are expected to reach $132.25 million, up 11.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 12% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][11]. Earnings Surprise Prediction - The Most Accurate Estimate for CPI Card Group is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.31%, which complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, CPI Card Group was expected to post earnings of $0.56 per share but only achieved $0.40, resulting in a surprise of -28.57%. Over the last four quarters, the company has beaten consensus EPS estimates twice [12][13]. Overall Assessment - CPI Card Group does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of its earnings release [16].

Core Viewpoint - SiriusPoint (SPNT) is anticipated to report a year-over-year decline in earnings due to lower revenues, with earnings expected to be $0.56 per share, reflecting a -1.8% change, and revenues projected at $720.1 million, down 3.1% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for August 4, and the stock may experience price movement based on whether the reported numbers exceed or fall short of expectations [2]. - The consensus EPS estimate has been revised down by 14.12% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that SiriusPoint has an Earnings ESP of 0%, suggesting no recent analyst revisions that differ from the consensus estimate [12]. - Despite a Zacks Rank of 2 (Buy), the combination of a 0% Earnings ESP makes it challenging to predict an earnings beat for SiriusPoint [12]. Historical Performance - In the last reported quarter, SiriusPoint had an earnings surprise of +88.46%, reporting $0.49 per share against an expected $0.26 [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Comparison - In contrast, MGIC Investment (MTG), another player in the insurance industry, is expected to post earnings of $0.7 per share, reflecting a -9.1% year-over-year change, with revenues projected at $306.76 million, up 0.4% [18][19]. - MGIC has an Earnings ESP of +2.37% and has consistently beaten consensus EPS estimates in the last four quarters, indicating a more favorable outlook compared to SiriusPoint [19].

Wall Street expects a year-over-year decline in earnings on lower revenues when MSA Safety (MSA) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than expectations. O ...

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its second-quarter 2025 results on August 4, before the market opens [1] - In the last reported quarter, the company achieved adjusted earnings per share (EPS) of $2.96, exceeding the Zacks Consensus Estimate by 1.37% [1] - The company has beaten earnings estimates in three of the last four quarters, with an average surprise of negative 0.09% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for Q2 revenues is $1.07 billion, reflecting a 6.3% increase from the previous year [2] - The Zacks Consensus Estimate for EPS is $3.31, indicating a rise of 35.7% year-over-year [2] - Earnings estimates have increased by 0.6% to $3.31 in the past 30 days [3] Performance Factors - The Companion Animal Group (CAG) is expected to show strong performance due to global net price improvements and higher volumes, particularly in diagnostics [4] - IDEXX VetLab consumables revenue growth is anticipated from higher price realization and volume increases, supported by an expanded active installed instrument base [4] - Reference laboratory diagnostic services are expected to see increased revenues from higher global price realization and testing volumes, although rapid assay revenues may be impacted by lower U.S. clinical visits [5] International and Innovation Impact - International CAG Diagnostic recurring revenues are likely to benefit from new business gains and an expanded premium instrument installed base [6] - IDEXX's recent innovations, such as the IDEXX Cancer Dx diagnostic panel, are expected to positively impact second-quarter revenues [7] - Growth in Veterinary Software, Services, and Diagnostic Imaging Systems is likely driven by higher subscription volumes and increased sales of diagnostic imaging systems [8] Segment Performance - The Water segment is projected to deliver solid revenues, benefiting from realized price increases and higher volumes, with an estimated 8.7% year-over-year improvement [10] - The Livestock, Poultry, and Dairy (LPD) division is expected to see a 3.9% year-over-year decrease in revenues for Q2 2025 [11] Earnings ESP and Zacks Rank - IDEXX Laboratories has an Earnings ESP of +0.34%, indicating a higher chance of beating estimates [12] - The company currently holds a Zacks Rank of 3 (Hold) [13]

Bit Digital, Inc. (BTBT) ended the recent trading session at $3.15, demonstrating a -2.48% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow saw an upswing of 0.47%, while the tech-heavy Nasdaq appreciated by 0.24%. Shares of the company have appreciated by 62.31% over the course of the past month, outperforming the Business Services sector's loss of 0.55%, and the S&P 500's gain of 4.61%.Investors will be eagerly watching for the performanc ...